{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T17:25:19Z","timestamp":1788715519557,"version":"build-2803163510"},"reference-count":19,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T00:00:00Z","timestamp":1610928000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Allergy Immunology"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Kawasaki disease (KD) is a significant febrile illness in children and is the leading cause of acquired pediatric heart disease in developed countries. Its recommended treatment is high\u2010dose intravenous immune globulin (IVIG) plus aspirin. However, IVIG\u2010related adverse events are seen frequently in this population. Premedication is commonly used to reduce this risk, but evidence supporting this practice is conflicting. Ultimately, practices vary among institutions and no standard guidelines regarding IVIG premedication currently exist.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Electronic medical records for pediatric patients presenting to an academic, tertiary care medical center diagnosed with KD and who received at least one dose of IVIG were reviewed for: patient demographics, treatment characteristics, premedication use, adverse events, and coronary abnormalities at discharge. Descriptive statistics were used to evaluate study findings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Sixty\u2010six patients receiving a total of 81 distinct IVIG administrations were evaluated. Most patients (64\/66, 97%) were premedicated prior to infusion with 26% of patients (17\/66) experiencing an IVIG\u2010related adverse event, totaling 25 documented adverse events. The most common events included chills and vomiting. Overall, the average duration of hospitalization was 4.37\u00a0days. Despite appropriate medication management, five patients (7.6%) developed coronary abnormalities.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Practitioners demonstrated a widespread use of premedication for IVIG. However, 26% of patients still experienced an adverse event. While premedication was not shown to have an adverse impact on patient outcomes, it also did not demonstrate a notable reduction from a historic adverse event incidence.<\/jats:p><\/jats:sec>","DOI":"10.1111\/pai.13432","type":"journal-article","created":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T20:19:29Z","timestamp":1608236369000},"page":"750-755","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Use of premedication with intravenous immune globulin in Kawasaki disease: A retrospective review"],"prefix":"10.1111","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9302-2481","authenticated-orcid":false,"given":"Elaine","family":"Liu","sequence":"first","affiliation":[{"name":"Rutgers The State University of New Jersey Ernest Mario School of Pharmacy Piscataway NJ USA"},{"name":"Jersey Shore University Medical Center Neptune NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Rutgers The State University of New Jersey Ernest Mario School of Pharmacy Piscataway NJ USA"},{"name":"Jersey Shore University Medical Center Neptune NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Siu","sequence":"additional","affiliation":[{"name":"Rutgers The State University of New Jersey Ernest Mario School of Pharmacy Piscataway NJ USA"},{"name":"Jersey Shore University Medical Center Neptune NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,1,18]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000484"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2005.02821.x"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2015.1044980"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1385\/CRIAI:29:3:173"},{"issue":"1","key":"e_1_2_9_6_1","first-page":"11","article-title":"Immediate adverse reactions to intravenous immunoglobulin in children: a single center experience","volume":"49","author":"Kaba S","year":"2017","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"e_1_2_9_7_1","volume-title":"(Human Immune Globulin Intravenous) [Package Insert]","author":"Carimune NF","year":"2018"},{"key":"e_1_2_9_8_1","volume-title":"(Human Immune Globulin Injection) [Package Insert]","author":"Gamunex C","year":"2020"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.08.033"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2006.08.011"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01701105"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01299"},{"issue":"3","key":"e_1_2_9_13_1","first-page":"174","article-title":"Use of methylprednisolone as prophylaxis for immediate adverse infusion reactions in hypogammaglobulinaemic patients receiving intravenous immunoglobulin: a controlled trial","volume":"24","author":"Roberton DM","year":"1998","journal-title":"Aust Paediatr J"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0b013e3182212589"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.9.1699"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1047951119000982"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.5415\/apallergy.2013.3.4.249"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2006.09.001"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.paf.0000188093.45675.ee"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270011399575"}],"container-title":["Pediatric Allergy and Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pai.13432","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/pai.13432","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pai.13432","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T21:09:33Z","timestamp":1693602573000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/pai.13432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,18]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1111\/pai.13432"],"URL":"https:\/\/doi.org\/10.1111\/pai.13432","archive":["Portico"],"relation":{},"ISSN":["0905-6157","1399-3038"],"issn-type":[{"value":"0905-6157","type":"print"},{"value":"1399-3038","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,18]]},"assertion":[{"value":"2020-07-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}